Loading patent…
AssigneeUniversity of Virginia Patent Foundation
InventorsRonald P. Taylor, William M. Sutherland, Craig Reist, Eleanor L. Wright, Donna Webb, Ronald Labuguen
Estimating the term…
Mammalian red blood cells are used to safely and rapidly neutralize and/or clear antigens or immunogens from the circulatory system by binding to the RBC a monoclonal antibody specific for a receptor (CR1) on the RBC, which monoclonal antibody is chemically bound to a second Mab specific for the antigen to be cleared from the circulatory system. These chemically cross-linked monoclonal antibody heteropolymers may be injected directly into the patient's circulatory system. Alternatively, red blood cells, extracted from the patient or provided by a suitable donor, are bound to the Mab complex and returned to the system.
A primate erythrocyte bound to a first monoclonal antibody at a CR1 receptor site for which said first monoclonal antibody is specific, said monoclonal antibody being cross-linked to a second monoclonal antibody specific for an antigen present in the primate circulatory system, said antigen being selected from the group consisting of virus, a microorganism and a protein, said primate erythrocyte bearing said first monoclonal antibody cross-linked to said second monoclonal antibody being effective for clearance of said antigen, in vivo, from said circulatory system.
Dependencies are inferred from the claim text.